Conditions: Postcholecystectomy Syndrome
Keywords: postcholecystectomy syndrome laparoscopic cholecystectomy Rowachol
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 138
Healthy volunteers: no

Brief summary:
Postcholecystectomy syndrome (PCS) includes a heterogeneous group of diseases, usually manifested by the presence of abdominal symptoms following gallbladder removal. The pathogenesis of PCS has not been identified; therefore there is no consensus of medical treatment on PCS. The Action of Rowachol are to inhibit hepatic 3-hydroxy-3-methylglutaric acid(HMG)-coenzyme A(CoA) reductase, to inhibits cholesterol nucleation in bile from patients with cholesterol gallstones, and to promote biliary lipid secretion.

The purpose of this study is to determine whether Rowachol is useful in the prevention of PCS and symptoms change after laparoscopic cholecystectomy

Detailed description:

Arms:
arm 1: Rowachol treatment with 200mg PO tid, on postoperative 1 days to 3 months arm 2: Placebo treatment with 200mg PO tid, on postoperative 1 days to 3 months

Interventions: intervention 1: Rowachol intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: